Risks in new drug development: Approval success rates for investigational drugs

Clinical Pharmacology & Therapeutics (2001) 69, 297–307; doi: 10.1067/mcp.2001.115446

[1]  D. Cox,et al.  Analysis of Survival Data. , 1985 .

[2]  Samuel B. Graves,et al.  Innovative output and firm size in the pharmaceutical industry , 1992 .

[3]  L Lasagna,et al.  New drug development in the United States from 1963 to 1990 , 1991, Clinical pharmacology and therapeutics.

[4]  R. Y. Nishimi,et al.  From the Office of Technology Assessment. , 1993, JAMA.

[5]  R. W. Hansen,et al.  Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry. , 1995, PharmacoEconomics.

[6]  J. DiMasi,et al.  Recombinant protein and therapeutic monoclonal antibody drug development in the United States from 1980 to 1994 , 1996, Clinical pharmacology and therapeutics.

[7]  Mark-M. Struck,et al.  Biopharmaceutical R&D Success Rates and Development Times , 1994, Bio/Technology.

[8]  E. M. Healy,et al.  The New Drug Approvals of 1996, 1997, and 1998: Drug Development Trends in the User Fee Era* , 2000 .

[9]  J. DiMasi,et al.  Success rates for new drugs entering clinical testing in the United States , 1995, Clinical pharmacology and therapeutics.

[10]  A. Trimble,et al.  New drug development by United States pharmaceutical firms: With analyses of trends in the acquisition and origin of drug candidates, 1963–1979 * , 1982, Clinical pharmacology and therapeutics.

[11]  Henry G. Grabowski,et al.  R&d Costs, Innovative Output and Firm Size in the Pharmaceutical Industry , 1995 .

[12]  W. Wardell,et al.  Development of new drugs originated and acquired by United States–owned pharmaceutical firms, 1963–1976 * , 1980, Clinical pharmacology and therapeutics.

[13]  J. DiMasi,et al.  New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical Firms , 2000 .

[14]  L Lasagna,et al.  New drug development in the United States from 1963 to 1992 , 1994, Clinical pharmacology and therapeutics.

[15]  L Lasagna,et al.  Cost of innovation in the pharmaceutical industry. , 1991, Journal of health economics.

[16]  Louis Lasagna,et al.  New drug development in the United States, 1963 through 1984 , 1988, Clinical pharmacology and therapeutics.

[17]  G. Tadmor,et al.  Biopharmaceuticals and Conventional Drugs: Clinical Success Rates , 1992, Bio/Technology.

[18]  W. Wardell,et al.  The rate of development of new drugs in the United States, 1963 through 1975 , 1978, Clinical pharmacology and therapeutics.

[19]  J. DiMasi,et al.  Measuring the Pace of New Drug Development in the User Fee ERA , 2000 .

[20]  D. Klein.  Improvement of phase III psychotropic drug trials by intensive phase II work. , 1991, Neuropsychopharmacology.

[21]  Success rates in the United States drug development system , 1984, Clinical pharmacology and therapeutics.

[22]  E. Clarke.  The NDA pipeline , 1983 .

[23]  Klein Df.  Improvement of phase III psychotropic drug trials by intensive phase II work. , 1991 .

[24]  J. Kane.  Obstacles to clinical research and new drug development in schizophrenia. , 1991, Schizophrenia bulletin.